NGL FINE-CHEM LIMITED

Regd Office: W 142(C) TTC MIDC Industrial Area



Pawane Village, Thane Belapur Road, Navi Mumbai 400 705

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTH ENDED 31ST DECEMBER, 2013

	PARTI						Rupees in lakhs
		Quarter ended			Nine Month Ended		Year ended
		31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012	31.03.2013
		(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	a. Net Sales / Income from Operations	1,740.31	1,940.44	1,433.59	5,752.97	3,819.87	5,514.84
	b. Other Operating Income	22.32	12.95	9.34	48.97	35.82	42.02
	Total Income	1,762.63	1,953.39	1,442.93	5,801.94	3,855.69	5,556.86
2	Total Expenditure :						
	a. Consumption of Raw Material	1,130.22	1,044.20	914.70	3,157.47	2,343.10	3,200.41
	b. (Increase)/Decrease in stock in trade and work in progress	(293.64)	(92.40)	(174.03)	(309.89)	(391.88)	(327.32)
	c. Employees Cost	205.17	191.13	167.09	572.37	428.09	590.65
	d. Depreciation	63.62	57.34	54.46	175.92	144.33	193.35
	e. Other Expenditure	517.35	490.69	364.42	1,527.65	968.48	1,354.65
	g. Total	1,622.72	1,690.96	1,326.64	5,123.52	3,492.12	5,011.74
3	Profit from operations before other income, finance costs (1 - 2)	139.91	262.43	116.29	678.42	363.57	545.12
4	Other Income	1.60	1.72	1.95	4.88	11.85	18.88
5	Profit from ordinary activities before finance costs (3 + 4)	141.51	264.15	118.24	683.30	375.42	564.00
6	Finance Costs	(35.66)	(28.59)	(29.78)	(93.22)	(86.92)	(118.04)
7	Profit from ordinary activities before tax (5 - 6)	105.85	235.56	88.46	590.08	288.50	445.96
8	Tax Expense	(42.71)	(76.31)	(32.01)	(198.21)	(104.36)	(153.52)
9	Net Profit for the Period (7 - 8)	63.14	159.25	56.45	391.87	184.14	292.44
10	Extra ordinary item (net of tax expenses)	-	-	1.52	-	1.52	1.52
11	Net Profit (9 - 10)	63.14	159.25	54.93	391.87	182.62	290.92
12	Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90	308.90	308.90
13	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	N.A	N.A	N.A	N.A	1,692.64
14	Earnings Per Share (EPS)						
	a) Basic	1.02	2.58	0.91	6.34	2.98	4.73
	b) Diluted	1.02	2.58	0.91	6.34	2.98	4.73
	PART II						
A 1	Particulars of Shareholding Public Shareholding						
	- Number of Shares	2,060,789	2,060,689	2,091,438	2,060,789	2,091,438	2,060,089
2	- Percentage of Shareholding Promoters and promoter group shareholding	33.36%	33.36%	33.85%	33.36%	33.85%	33.36%
2	a) Pledged / Encumbered						
	- Number of Shares		_	_			
	- Percentage of shares (as a % of the total shareholding of promoter and promoter	-		_			_
	group)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	- Percentage of shares (as a % of the total share capital of the company)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	b) Non-encumbered						
	- Number of Shares	4,117,235	4,119,335	4,086,586	4,117,235	4,086,586	4,117,935
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%		
	- Percentage of shares (as a % of the total share capital of the company)	66.64%	66.64%	66.15%	66.64%	66.15%	66.65%
	Particulars	3 months Ended December 31, 2013					
в	Investors Complaints						
	Pending at the beginning of the quarter			0			
	Received during the quarter Disposed off during the quarter			0			
	Disposed off during the quarter	0					
	Remaining unresloved at the end of the quarter	0					

1. The above results were reviewed by the Audit Committee and have been taken on record by the Board of Directors of the Company at their meeting held on January 29, 2014

2 The Statutory Auditors have carried out a limited review of the quarter & nine month ended 31st December 2013

3 The Company's operations consist only of one segment i.e. pharmaceuticals, hence Segment Reporting required under AS17 is not applicable.

4 The figures of the corresponding period have been regrouped wherever necessary.

For and On behalf of Board of Directors,

SD/-Rahul Nachane *Managing Director*